Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Jan;18(1):51-4.

[Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer]

[Article in Chinese]
Affiliations
  • PMID: 8732114
Clinical Trial

[Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer]

[Article in Chinese]
J Wang et al. Zhonghua Zhong Liu Za Zhi. 1996 Jan.

Abstract

A randomized trial of intracavitary microwave hyperthermia combined with external irradiation (R + H) versus radiation (R) alone in the treatment of esophageal cancer was performed from Feb. 1986 to Feb. 1988. In the R group, radiation was given by 8 MV X-ray with 2 Gy/fraction, 5 fractions per week with a total dose of 60 Gy/6 weeks. In the R + H group, the radiation was given as R group but with a total dose of 40 Gy/4 weeks. Intracavitary 915 MHz microwave hyperthermia was given with a nominal temperature of 43.5 degrees C at the margin of the tumor surface, 45 minutes/session, 1-2 sessions/week for 4-8 sessions. The 1-, 3-, and 5-year survival rates in R + H group were 81.2% (48/59 cases), 42.4% (25/59) and 23.7% (14/59), while in the R group 59.0% (39/66 cases), 24.2% (16/66) and 16.7% (11/66) respectively. The differences in 1- and 3-year survival rates were statistically significant (P < 0.05) between the 2 groups. Using the thermal dose T90 analysis, after the cases with T90 < 43 degrees C (insufficient thermal dose) were eliminated, 52 cases with T90 equal to or higher than 43 degrees C had 1, 3, and 5 year survival rates of 84.6%, 44.2% and 26.9%, respectively. Statistically significant differences in the 2 groups were also limited only to 1- and 3-year survivals. Higher 5-year survivals is anticipated if more cases are studied.

PubMed Disclaimer